{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:22:42Z","timestamp":1791235362992,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","award":["198168"],"award-info":[{"award-number":["198168"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.ejca.2024.113584","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T16:49:01Z","timestamp":1706806141000},"page":"113584","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Impact of molecular profile on prognosis and relapse pattern in low and intermediate risk endometrial cancer"],"prefix":"10.1016","volume":"200","author":[{"given":"Kristina","family":"Lindemann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanja","family":"Kildal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kleppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari Anne R.","family":"Tobin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manohar","family":"Pradhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria X.","family":"Isaksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ljiljana","family":"Vlatkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e5vard E.","family":"Danielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar B.","family":"Kristensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne A.","family":"Askautrud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ejca.2024.113584_bib1","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/s41416-018-0310-8","article-title":"Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy","volume":"119","author":"Wortman","year":"2018","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2024.113584_bib2","doi-asserted-by":"crossref","first-page":"e631","DOI":"10.1016\/j.ijrobp.2011.04.013","article-title":"Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. Randomized Controlled Trial Research Support, Non-U.S. Gov't","volume":"81","author":"Creutzberg","year":"2011","journal-title":"Int J Radiat Oncol, Biol, Phys"},{"issue":"6","key":"10.1016\/j.ejca.2024.113584_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13061367","article-title":"Salvage radiation for pelvic relapse after surgically treated endometrial cancer","volume":"13","author":"Lindemann","year":"2021","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.ejca.2024.113584_bib4","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1097\/IGC.0b013e3182a5e77d","article-title":"Omitting adjuvant radiotherapy in endometrial cancer increases the rate of locoregional recurrences but has no effect on long-term survival: the Danish Endometrial Cancer Study","volume":"23","author":"Ortoft","year":"2013","journal-title":"Int J Gynecol Cancer: J Int Gynecol Cancer Soc"},{"issue":"5","key":"10.1016\/j.ejca.2024.113584_bib5","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cncr.30496","article-title":"Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer","volume":"123","author":"Talhouk","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2024.113584_bib6","doi-asserted-by":"crossref","DOI":"10.1007\/s00428-020-03007-z","article-title":"ESGO\/ESTRO\/ESP Guidelines for the management of patients with endometrial carcinoma","author":"Concin","year":"2021","journal-title":"Virchows Arch"},{"issue":"2","key":"10.1016\/j.ejca.2024.113584_bib7","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/ijgo.14923","article-title":"FIGO staging of endometrial cancer: 2023","volume":"162","author":"Berek","year":"2023","journal-title":"Int J Gynaecol Obstet: Organ Int Fed Gynaecol Obstet"},{"issue":"9","key":"10.1016\/j.ejca.2024.113584_bib8","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.annonc.2022.05.009","article-title":"Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Oaknin","year":"2022","journal-title":"Ann Oncol: J Eur Soc Med Oncol \/ ESMO"},{"issue":"12","key":"10.1016\/j.ejca.2024.113584_bib9","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.47372","article-title":"Relevance of molecular profiling in patients with low-grade endometrial cancer","volume":"5","author":"Vrede","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.ejca.2024.113584_bib10","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41416-018-0187-6","article-title":"L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile","volume":"119","author":"Kommoss","year":"2018","journal-title":"Br J Cancer"},{"issue":"21","key":"10.1016\/j.ejca.2024.113584_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14215429","article-title":"Integrated biomarker analysis reveals L1CAM as a potential stratification marker for no specific molecular profile high-risk endometrial carcinoma","volume":"14","author":"Ravaggi","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2024.113584_bib12","unstructured":"Board WCoTE. 2020 WHO Classification of Female Genital Tumors. 5. ed. vol 4. International Agency for Research on Cancer (IARC); 2020."},{"issue":"1","key":"10.1016\/j.ejca.2024.113584_bib13","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/annonc\/mdv484","article-title":"ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up","volume":"27","author":"Colombo","year":"2016","journal-title":"Ann Oncol: J Eur Soc Med Oncol \/ ESMO"},{"issue":"Suppl 1","key":"10.1016\/j.ejca.2024.113584_bib14","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1097\/PGP.0000000000000488","article-title":"Interpretation of P53 immunohistochemistry in endometrial carcinomas: toward increased reproducibility","volume":"38","author":"Kobel","year":"2019","journal-title":"Int J Gynecol Pathol"},{"issue":"15","key":"10.1016\/j.ejca.2024.113584_bib15","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1093\/jnci\/djt144","article-title":"L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation","volume":"105","author":"Zeimet","year":"2013","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.ejca.2024.113584_bib16","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/path.5372","article-title":"Interpretation of somatic POLE mutations in endometrial carcinoma","volume":"250","author":"Leon-Castillo","year":"2020","journal-title":"J Pathol"},{"issue":"3","key":"10.1016\/j.ejca.2024.113584_bib17","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S2468-1253(16)30014-0","article-title":"Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study","volume":"1","author":"Domingo","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"13","key":"10.1016\/j.ejca.2024.113584_bib18","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1093\/jnci\/djm024","article-title":"Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials","volume":"99","author":"Punt","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.ejca.2024.113584_bib19","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ijgo.2009.02.012","article-title":"Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Introductory","volume":"105","author":"Pecorelli","year":"2009","journal-title":"Int J Gynaecol Obstet: Organ Int Fed Gynaecol Obstet"},{"key":"10.1016\/j.ejca.2024.113584_bib20","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.23.00062","article-title":"Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer","author":"Horeweg","year":"2023","journal-title":"J Clin Oncol: J Am Soc Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2024.113584_bib21","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ygyno.2022.02.024","article-title":"Time to first recurrence, pattern of recurrence, and survival after recurrence in endometrial cancer according to the molecular classification","volume":"165","author":"Siegenthaler","year":"2022","journal-title":"Gynecol Oncol"},{"issue":"9717","key":"10.1016\/j.ejca.2024.113584_bib22","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S0140-6736(09)62163-2","volume":"375","author":"Nout","year":"2010","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.ejca.2024.113584_bib23","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1200\/JCO.2010.32.4590","article-title":"Long-term outcome and quality of life of patients with endometrial carcinoma treated with or without pelvic radiotherapy in the post operative radiation therapy in endometrial carcinoma 1 (PORTEC-1) trial","volume":"29","author":"Nout","year":"2011","journal-title":"J Clin Oncol: J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2024.113584_bib24","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.20.00549","article-title":"Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy","author":"Leon-Castillo","year":"2020","journal-title":"J Clin Oncol: J Am Soc Clin Oncol"},{"issue":"7447","key":"10.1016\/j.ejca.2024.113584_bib25","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Cancer Genome Atlas Research","year":"2013","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ejca.2024.113584_bib26","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ygyno.2019.10.028","article-title":"Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer","volume":"156","author":"Stasenko","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2024.113584_bib27","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/annonc\/mdy058","article-title":"Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series","volume":"29","author":"Kommoss","year":"2018","journal-title":"Ann Oncol: J Eur Soc Med Oncol ESMO"},{"issue":"1","key":"10.1016\/j.ejca.2024.113584_bib28","first-page":"109","article-title":"Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program","volume":"33","author":"Consortium","year":"2022","journal-title":"Int J Gynecol Cancer: J Int Gynecol Cancer Soc"},{"issue":"14","key":"10.1016\/j.ejca.2024.113584_bib29","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1002\/cncr.33516","article-title":"Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: an individual patient data meta-analysis","volume":"127","author":"McAlpine","year":"2021","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.ejca.2024.113584_bib30","doi-asserted-by":"crossref","DOI":"10.1200\/GO.22.00384","article-title":"QPOLE: a quick, simple, and cheap alternative for POLE sequencing in endometrial cancer by multiplex genotyping quantitative polymerase chain reaction","author":"Van den Heerik","year":"2023","journal-title":"JCO Glob Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2024.113584_bib31","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1038\/s41436-019-0489-y","article-title":"The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome","volume":"21","author":"Crosbie","year":"2019","journal-title":"Genet Med"},{"issue":"23","key":"10.1016\/j.ejca.2024.113584_bib32","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ejca.2024.113584_bib33","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/s41416-023-02141-0","article-title":"Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry","volume":"128","author":"Vermij","year":"2023","journal-title":"Br J Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924000601?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924000601?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:42:56Z","timestamp":1760733776000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924000601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":33,"alternative-id":["S0959804924000601"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.113584","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of molecular profile on prognosis and relapse pattern in low and intermediate risk endometrial cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.113584","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"113584"}}